Skip to main content
. 2008 Feb 1;118(3):1027–1039. doi: 10.1172/JCI32020

Figure 9. Protective efficacy of P14 CD8 T cells from IL-7 treated mice.

Figure 9

Naive Thy1.1+ve or Ly5.1+ve P14 CD8 T cells were adoptively transferred into congenic Thy1.2/C57BL/6 mice and infected with LCMV-Arm. Between days 7 and 14 after infection, mice received daily injections of IL-7 or PBS. (A and B) Secondary expansion and protective immunity of P14 CD8 T cells from IL-7–treated mice. On day 15 after infection, T cells were purified from the spleens of LCMV-Arm–infected PBS- and IL-7–treated mice, and equal numbers of in vivo–activated P14 CD8 T cells were adoptively transferred into Thy1.2/C57BL/6 mice. Recipient mice were challenged with LCMV-clone 13 one day after cell transfer; 5 days after LCMV-clone 13 challenge, the secondary expansion of P14 CD8 T cells in the spleen (A) and viral titers in the lung and liver (B) were quantitated. (C) Cytotoxic activity of P14 CD8 T cells from IL-7–treated mice. On day 15 after primary LCMV infection, the number of P14 CD8 T cells from the spleen were normalized between samples and tested for cytotoxic activity at the indicated effector/target ratios using GP33-pulsed (GP33 peptide) or unpulsed (no peptide) MC57 target cells directly ex vivo. (D) Antigen-induced proliferation of P14 CD8 T cells from IL-7–treated mice. On day 15 after infection, CFSE-labeled splenocytes were stimulated in vitro with GP33 peptide for 60 hours. The histograms show CFSE fluorescence in gated P14 CD8 T cells. Note the cell division–induced dilution of CFSE in P14 CD8 T cells from IL-7–treated mice.